AHR
Aryl hydrocarbon receptor
As of the edition of 20 October 2026, AHR (aryl hydrocarbon receptor, UniProt P35869) has 4 drugs tested at it and 6 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35869
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 3
- Disease areas
- Skin and connective tissue; Immune system; Inherited and neonatal; Cancer; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Blood and lymph
- Registered trials of its drugs
- 38
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 2 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tapinarof | Marketed | Phase 4 | Ends 2038 |
| Afp-464 free base | Stopped | Phase 2 | none listed |
| BAY2416964 | Stopped | Phase 1 | none listed |
| IK-175 | Status not established | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Undetermined | 2 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Organon | Route B |
| Bayer | Route A |
| Japan Tobacco | Route B |
The other 3 companies at AHR
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at AHR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.